Intervention
Partial reprogramming (OSK)
- Works
- 1,308
- Clinical trials
- 49
- Total citations
- 99,123
- Open access
- 1,165
Evidence brief
Based on the provided sources, partial reprogramming utilizing factors such as OSK is investigated as a strategy to rejuvenate aged cells (specifically mesenchymal stem cells) and mitigate replicative senescence without inducing unintended pluripotent conversion [10]. Epigenetic modifications play a critical role in normal development, tissue maintenance, and disease states like cancer [1, 2], highlighting the delicate balance required when manipulating cellular landscapes.
Open questions remain regarding the safety and translational application of partial reprogramming, particularly concerning the risks of malignant transformation, altered gene function, and loss of cell identity [1, 2, 10]. While innovative delivery platforms (such as circRNA systems) are being developed to achieve safe rejuvenation without full pluripotent conversion [10], the overall strength of evidence specifically addressing OSK partial reprogramming in these sources is preliminary and primarily focused on preclinical or methodological feasibility [10].